Core Viewpoint - Fosen Pharmaceutical's wholly-owned subsidiary has received approval from the National Medical Products Administration of China for the launch of "Compound Potassium Hydrogen Phosphate Injection," which is intended as a phosphate supplement for patients unable to receive oral or enteral nutrition [1][2] Group 1: Product Details - The "Compound Potassium Hydrogen Phosphate Injection" is primarily used for patients with hypophosphatemia and those requiring parenteral nutrition supplementation [1] - The product is a new generation phosphate-potassium compound formulation that quickly corrects phosphate deficiency while simultaneously stabilizing cell membrane potential to prevent risks associated with hypophosphatemia [1] - The domestic sales forecast for the injection is projected to be CNY 343 million in 2023 and CNY 413 million in 2024 [1] Group 2: Market Position and Benefits - The injection is classified as a Category B product by the National Healthcare Security Administration, highlighting its safety, rapid absorption, dual phosphate-potassium supplementation, and alignment with multiple clinical guidelines [1] - The formulation of the injection is consistent with the reference product, ensuring quality control that meets or exceeds the original product, thereby safeguarding patient safety [1] - The product offers significant risk-benefit advantages in improving laboratory results and clinical symptoms for both adult and pediatric patients with hypophosphatemia [1]
福森药业(01652.HK)："复合磷酸氢钾注射液"获批上市